{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-046085","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.947984+00:00","generated_at":"2026-05-24T03:53:33.400077+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"Clearside posts Q4 net loss $7.3M; cash to Q4 2025; FDA aligns on CLS-AX Phase 3 in wet AMD","bullets":["Q4 2024 net loss $7.3M ($0.10/sh) vs $4.8M ($0.08) in Q4 2023; FY loss $34.4M ($0.47) vs $32.5M ($0.53).","Cash $20.0M at Dec 31, 2024; expected to fund operations into Q4 2025.","FDA alignment on Phase 3 for CLS-AX in wet AMD: two non-inferiority trials, sham control, after positive Phase 2b.","Partner Arctic Vision NDA for ARCATUS (XIPERE) in uveitic macular edema accepted in China; also approved in Australia and Singapore.","Tony Gibney appointed Chair of Board effective November 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-046085","json":"https://secwatch.observer/filing/0000950170-25-046085.json","markdown":"https://secwatch.observer/filing/0000950170-25-046085.md","text":"https://secwatch.observer/filing/0000950170-25-046085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017025046085/0000950170-25-046085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017025046085/clsd-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:53:33.400077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}